|
1
|
American Cancer Society. Cancer Facts
& Figures 2013. Atlanta, GA: 2013
|
|
2
|
Kim R and Saif MW: Is there an optimal
neoadjuvant therapy for locally advanced pancreatic cancer? JOP.
8:279–288. 2007.
|
|
3
|
Oikonomopoulos GM, Huber KE, Syrigos KN
and Saif MW: Locally advanced pancreatic cancer. JOP. 14:126–128.
2013.
|
|
4
|
Ng J, Zhang C, Gidea-Addeo D and Saif MW:
Locally advanced pancreatic adenocarcinoma: update and progress.
JOP. 13:155–158. 2012.
|
|
5
|
Gastrointestinal Tumor Study Group.
Treatment of locally unresectable carcinoma of the pancreas:
comparison of combined-modality therapy (chemotherapy plus
radiotherapy) to chemotherapy alone. J Natl Cancer Inst.
80:751–755. 1988.
|
|
6
|
Gastrointestinal Tumor Study Group.
Radiation therapy combined with Adriamycin or 5-fluorouracil for
the treatment of locally unresectable pancreatic carcinoma. Cancer.
56:2563–2568. 1985.
|
|
7
|
Moertel CG, Frytak S, Hahn RG, et al;
Gastrointestinal Study Group. Therapy of locally unresectable
pancreatic carcinoma: a randomized comparison of high dose (6000
rads) radiation alone, moderate dose radiation (4000 rads +
5-fluorouracil), and high dose radiation + 5-fluorouracil: The
Gastrointestinal Tumor Study Group. Cancer. 48:1705–1710. 1981.
|
|
8
|
Klaassen DJ, MacIntyre JM, Catton GE,
Engstrom PF and Moertel CG: Treatment of locally unresectable
cancer of the stomach and pancreas: a randomized comparison of
5-fluorouracil alone with radiation plus concurrent and maintenance
5-fluorouracil - an Eastern Cooperative Oncology Group study. J
Clin Oncol. 3:373–378. 1985.
|
|
9
|
Cohen SJ, Dobelbower R Jr, Lipsitz S, et
al: A randomized phase III study of radiotherapy alone or with
5-fluorouracil and mitomycin-C in patients with locally advanced
adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group
study E8282. Int J Radiat Oncol Biol Phys. 62:1345–1350. 2005.
|
|
10
|
Moertel CG, Childs DS Jr, Reitemeier RJ,
Colby MY Jr and Holbrook MA: Combined 5-fluorouracil and
supervoltage radiation therapy of locally unresectable
gastrointestinal cancer. Lancet. 2:865–867. 1969.
|
|
11
|
Whittington R, Neuberg D, Tester WJ,
Benson AB III and Haller DG: Protracted intravenous fluorouracil
infusion with radiation therapy in the management of localized
pancreaticobiliary carcinoma: a phase I Eastern Cooperative
Oncology Group Trial. J Clin Oncol. 13:227–232. 1995.
|
|
12
|
Ishii H, Okada S, Tokuuye K, Nose H, et
al: Protracted 5-fluorouracil infusion with concurrent radiotherapy
as a treatment for locally advanced pancreatic carcinoma. Cancer.
79:1516–1520. 1997.
|
|
13
|
Burris HA III, Moore MJ, Andersen J, et
al: Improvements in survival and clinical benefit with gemcitabine
as first-line therapy for patients with advanced pancreas cancer: a
randomized trial. J Clin Oncol. 15:2403–2413. 1997.
|
|
14
|
Blackstock AW, Tepper JE, Niedwiecki D, et
al: Cancer and leukemia group B (CALGB) 89805: phase II
chemoradiation trial using gemcitabine in patients with
locoregional adenocarcinoma of the pancreas. Int J Gastrointest
Cancer. 34:107–116. 2003.
|
|
15
|
Moore AM, Cardenes H, Johnson CS, et al: A
phase II study of gemcitabine in combination with radiation therapy
in patients with localized, unresectable, pancreatic cancer: A
hoosier oncology group trial. ASCO Annual Meeting. 22:(Abstract
4105). 2004.
|
|
16
|
Epelbaum R, Rosenblatt E, Nasrallah S,
Faraggi D, Gaitini D, Mizrahi S and Kuten A: Phase II study of
gemcitabine combined with radiation therapy in patients with
localized, unresectable pancreatic cancer. J Surg Oncol.
81:138–143. 2002.
|
|
17
|
Haddock MG, Swaminathan R, Foster NR, et
al: Gemcitabine, cisplatin, and radiotherapy for patients with
locally advanced pancreatic adenocarcinoma: results of the North
Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol.
25:2567–2572. 2007.
|
|
18
|
Miwa M, Ura M, Nishida M, et al: Design of
a novel oral fluoropyrimidine carbamate, capecitabine, which
generates 5-fluorouracil selectively in tumours by enzymes
concentrated in human liver and cancer tissue. Eur J Cancer.
34:1274–1281. 1998.
|
|
19
|
Sawada N, Ishikawa T, Sekiguchi F, Tanaka
Y and Ishitsuka H: X-ray irradiation induces thymidine
phosphory-lase and enhances the efficacy of capecitabine (Xeloda)
in human cancer xenografts. Clin Cancer Res. 5:2948–2953. 1999.
|
|
20
|
Blanquicett C, Saif MW, Buchsbaum DJ, et
al: Antitumor efficacy of capecitabine and celecoxib in irradiated
and lead-shielded, contralateral human BxPC-3 pancreatic cancer
xenografts: clinical implications of abscopal effects. Clin Cancer
Res. 11:8773–8781. 2005.
|
|
21
|
Saif MW, Eloubeidi MA, Russo S, et al:
Phase I study of capecitabine with concomitant radiotherapy for
patients with locally advanced pancreatic cancer: expression
analysis of genes related to outcome. J Clin Oncol. 23:8679–8687.
2005.
|
|
22
|
Saif MW, Black G, Roy S, et al: Phase II
study of capecitabine with concomitant radiotherapy for patients
with locally advanced pancreatic cancer: up-regulation of thymidine
phosphorylase. Cancer J. 13:247–256. 2007.
|
|
23
|
Huang H, Jiang Z, Wang T, et al:
Single-agent capecitabine maintenance therapy after response to
capecitabine-based combination chemotherapy in patients with
metastatic breast cancer. Anticancer Drugs. 23:718–723. 2012.
|
|
24
|
Chibaudel B, Maindrault-Goebel F, Lledo G,
et al: Can chemotherapy be discontinued in unresectable metastatic
colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol.
27:5727–5733. 2009.
|
|
25
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
|
|
26
|
National Cancer Institute. Common
Terminology Criteria for Adverse Events. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
Accessed September 13, 2013
|
|
27
|
Saif MW, Hashmi S, Zelterman D, Almhanna K
and Kim R: Capecitabine vs continuous infusion 5-FU in neoadjuvant
treatment of rectal cancer. A retrospective review. Int J
Colorectal Dis. 23:139–145. 2008.
|
|
28
|
Van Cutsem E, Twelves C, Cassidy J, et al:
Oral capecitabine compared with intravenous fluorouracil plus
leucovorin in patients with metastatic colorectal cancer: results
of a large phase III study. J Clin Oncol. 19:4097–4106. 2001.
|
|
29
|
Hoff PM, Ansari R, Batist G, et al:
Comparison of oral capecitabine versus intravenous fluorouracil
plus leucovorin as first-line treatment in 605 patients with
metastatic colorectal cancer: results of a randomized phase III
study. J Clin Oncol. 19:2282–2292. 2001.
|
|
30
|
Saif MW, Shi N and Zelt S: Capecitabine
treatment patterns in patients with gastroesophageal cancer in the
United States. World J Gastroenterol. 15:4415–4422. 2009.
|
|
31
|
Cassidy J, Twelves C and Van Cutsem E;
Capecitabine Colorectal Cancer Study Group: First-line oral
capecitabine therapy in metastatic colorectal cancer: a favorable
safety profile compared with intravenous 5-fluorouracil/leucovorin.
Ann Oncol. 13:566–575. 2002.
|
|
32
|
Kato H, Ichinose Y, Ohta M, et al; Japan
Lung Cancer Research Group on Postsurgical Adjuvent Chemotherapy. A
randomized trial of adjuvant chemotherapy with uracil-tegafur for
adenocarcinoma of the lung. N Engl J Med. 350:1713–1721. 2004.
|
|
33
|
Miyashiro I, Furukawa H and Sasako M;
Gastric Cancer Surgical Study Group; Japan Clinical Oncology Group.
No survival benefit with adjuvant chemotherapy for serosa-positive
gastric cancer: Randomized trial of adjuvant chemotherapy with
cisplatin followed by oral fluorouracil in serosa-positive gastric
cancer. Japan Clinical Oncology Group 9206-2. In: ASCO
Gastrointestinal Cancers Symposium; abstract 4. 2005
|
|
34
|
Sun JF, Wu RR, Norris C, Noone AM,
Amankwa-Sakyi M, Slack R and Marshall JL: Safety of chronic
low-dose capecitabine as maintenance therapy in gastrointestinal
cancers. Gastrointest Cancer Res. 3:134–140. 2009.
|
|
35
|
Saif MW, Wood TE, McGee PJ and Diasio RB:
Peripheral neuropathy associated with capecitabine. Anticancer
Drugs. 15:767–771. 2004.
|
|
36
|
Cartwright TH, Cohn A, Varkey JA, et al:
Phase II study of oral capecitabine in patients with advanced or
metastatic pancreatic cancer. J Clin Oncol. 20:160–164. 2001.
|
